Heparin-Induced Thrombocytopenia Market Size (7MM) is Expected to Grow at a Significant CAGR by 2034 | DelveInsight

DelveInsight's "Heparin-Induced Thrombocytopenia Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Heparin-Induced Thrombocytopenia, historical and forecasted epidemiology as well as the Heparin-Induced Thrombocytopenia market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Explore the intricate details of the Heparin-Induced Thrombocytopenia Market Report @ https://www.delveinsight.com/report-store/heparin-induced-thrombocytopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Heparin-Induced Thrombocytopenia Market Report
• The heparin-induced thrombocytopenia market size in the 7MM is estimated to be around ~USD 128 million, in 2023.
• The United States comprised roughly 50% of the overall market within the 7MM.
• Among the EU4 and the UK, Germany held the largest market share in 2023, comprising approximately 40% of the total market size.
• In 2023, Japan contributed approximately ~USD 3 million to the market size, with expectations of steady growth projected until 2034.
• Argatroban accounted for the largest market share of ~USD 62 million in 2023 in the 7MM.

Get a Free sample for the Heparin-Induced Thrombocytopenia Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/heparin-induced-thrombocytopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Heparin-Induced Thrombocytopenia Epidemiology Segmentation in the 7MM
• Total Incident Cases of Heparin-Induced Thrombocytopenia
• Type-specific Cases of Heparin-Induced Thrombocytopenia
• Age-specific Cases of Heparin-Induced Thrombocytopenia
• Total cases of Heparin-Induced Thrombocytopenia across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan
In 2023, approximately 220,800 diagnosed incident cases of Heparin-Induced Thrombocytopenia were recorded, with the United States holding the largest share at around 51% of the total cases. Among the EU4 and the UK, Germany recorded the highest incident cases, followed by France, contributing approximately 23% of the total incident cases. In the US, total incident cases in type-specific heparin exposure were estimated at ~107,000 for unfractionated heparin (UFH) and ~6,000 for low molecular-weight heparin (LMWH) in 2023.

Download the report to understand which factors are driving Heparin-Induced Thrombocytopenia epidemiology trends @ https://www.delveinsight.com/report-store/heparin-induced-thrombocytopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Heparin-Induced Thrombocytopenia Disease Understanding and Treatment Algorithm
Heparin-Induced Thrombocytopenia is a severe and potentially life-threatening immune-mediated adverse reaction triggered by the administration of heparin. It is characterized by a rapid decrease in platelet count occurring 5-14 days after the initiation of heparin therapy, primarily caused by the formation of antibodies against platelet factor 4 (PF4) and heparin. These antibodies induce platelet activation, leading to a prothrombotic state and increased venous and arterial thrombosis risk.

Diagnosis is based on a combination of clinical assessment, laboratory tests, and the 4Ts scoring system. Criteria include a normal platelet count before heparin initiation, thrombocytopenia defined as a drop in platelet count by 30% to 50% from baseline, onset typically 5-10 days after initiation of treatment (earlier with prior heparin exposure within 100 days), an acute thrombotic event, exclusion of other causes of thrombocytopenia, resolution of thrombocytopenia after cessation of heparin, and antibody seroconversion.

Management involves immediate discontinuation of all forms of heparin and initiation of alternative non-heparin anticoagulants, such as direct thrombin inhibitors (e.g., argatroban, bivalirudin) or factor Xa inhibitors (e.g., fondaparinux, danaparoid), along with close monitoring of platelet counts and clinical signs of thrombosis and bleeding.

Heparin-Induced Thrombocytopenia Marketed Drugs
• ANGIOMAX (bivalirudin) - Sandoz
Bivalirudin is an inhibitor of thrombin used as an anticoagulant, reversibly binding thrombin at the catalytic site and anion-binding exosite to prevent fibrin formation and activation of Factor XIIIa and other coagulation factors. Administered intravenously, it is indicated for patients undergoing percutaneous coronary intervention (PCI), including those with Heparin-Induced Thrombocytopenia or Heparin-Induced Thrombocytopenia with thrombosis syndrome.
• Argatroban - Sandoz/Fresenius Kabi/Hikma Pharma
A synthetic direct thrombin inhibitor used in patients with thrombosis and Heparin-Induced Thrombocytopenia. It reversibly binds to the catalytic site of thrombin, blocking activation of clotting Factors V, VIII, and XII. Given intravenously and metabolized in the liver with a half-life of about 50 minutes, it may be suitable for patients with renal dysfunction.

Heparin-Induced Thrombocytopenia Emerging Drugs
• VLX-1005 - Veralox Therapeutics
A first-in-class, selective small molecule inhibitor of 12-lipoxygenase, blocking the 12-LOX pathway responsible for platelet activation in Heparin-Induced Thrombocytopenia. Administered via IV and oral routes, preclinical data have shown it halts immune-driven platelet activation and thrombosis. VLX-1005 received FDA fast track designation in June 2022 based on positive Phase I results and is currently being studied in a Phase II trial (NCT05785819). In June 2023, Veralox Therapeutics announced the appointment of Jonathan Mow as its new CEO, alongside USD 24 million in funding to advance VLX-1005 through a Phase IIa proof-of-concept study.

Discover more about therapies set to grab major Heparin-Induced Thrombocytopenia market share @ https://www.delveinsight.com/sample-request/heparin-induced-thrombocytopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Heparin-Induced Thrombocytopenia Market Outlook
The primary treatment approach involves discontinuing unfractionated heparin (UFH) or low molecular-weight heparin (LMWH) in patients suspected of or diagnosed with Heparin-Induced Thrombocytopenia, initiating therapy with an alternative anticoagulant. LMWH is not an appropriate alternative if the condition develops during UFH treatment due to cross-reactivity. Argatroban and bivalirudin are both non-cross reacting; danaparoid demonstrates cross reactivity rarely observed in vivo, while fondaparinux is highly immunogenic but not well recognized by anti-fondaparinux-PF4 antibodies, suggesting a low risk of developing the condition. Warfarin, especially used in isolation, can increase the risk of microvascular thrombosis and its introduction should be delayed until substantial resolution of thrombocytopenia.

Several novel oral anticoagulants (e.g., rivaroxaban, dabigatran, apixaban) may also be beneficial, particularly in cases refractory to standard therapies, though none currently have FDA approval for this indication. With the anticipated entry of therapies featuring novel mechanisms, the treatment scenario is expected to experience significant growth during the forecast period (2024-2034), addressing a dire unmet need in the current landscape.

Heparin-Induced Thrombocytopenia Drugs Uptake
Various key players are leading the treatment landscape of Heparin-Induced Thrombocytopenia, including Veralox Therapeutics, Sandoz, Fresenius Kabi, Hikma Pharm, and others, alongside Pfizer, Sanofi, Abbott Laboratories, Johnson & Johnson, and Bristol Myers Squibb. The drug chapters section provides an in-depth evaluation of late-stage pipeline drugs (Phase II), covering pharmacological mechanisms, designations, approval status, patent information, and a comprehensive analysis of the pros and cons of each drug, along with the most recent news and press releases.

To know more about Heparin-Induced Thrombocytopenia companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/heparin-induced-thrombocytopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Scope of the Heparin-Induced Thrombocytopenia Market Report
• Study Period: 2020-2034
• Forecast Period: 2024-2034
• Coverage: 7MM (United States, EU4 [Germany, France, Italy, and Spain], the United Kingdom, and Japan)
• Heparin-Induced Thrombocytopenia Therapeutic Assessment: current marketed and emerging therapies
• Heparin-Induced Thrombocytopenia Companies: Pfizer, Sanofi, Abbott Laboratories, Johnson & Johnson, Bristol Myers Squibb, Veralox Therapeutics, and others
• Heparin-Induced Thrombocytopenia Epidemiology Segmentation: Total Incident Cases, Type-specific Cases, Age-specific Cases, Total Cases
• KOL's views, Analyst's views, SWOT and Conjoint Analysis

Table of Contents
1. Key Insights
2. Report Introduction
3. Heparin-induced Thrombocytopenia (HIT) Market Overview at a Glance
4. Executive Summary of Heparin-induced Thrombocytopenia (HIT)
5. Key Events
6. Disease Background and Overview
7. Treatment of Heparin-induced Thrombocytopenia
8. Methodology
9. Heparin-induced Thrombocytopenia Epidemiology and Patient Population
10. Heparin-induced Thrombocytopenia Patient Journey
11. Heparin-induced Thrombocytopenia Marketed Therapies
12. Heparin-induced Thrombocytopenia Emerging Therapies
13. Heparin-induced Thrombocytopenia (HIT): Seven Major Market Analysis
14. KOL Views
15. SWOT Analysis
16. Heparin-induced Thrombocytopenia Unmet Needs
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.